<DOC>
	<DOCNO>NCT01478178</DOCNO>
	<brief_summary>The purpose Phase 1/2 , open-label , single-arm study determine safety maximal tolerate dose ( MTD ) VAL-083 patient recurrent malignant glioma . Pharmacokinetic ( PK ) property explore tumor response treatment evaluate .</brief_summary>
	<brief_title>Safety Study VAL-083 Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>Recurrent glial tumor brain continue one challenging malignancy treat . Median survival patient recurrent disease approximately 6 month glioblastoma multiforme . Bevacizumab use treatment recurrent disease ; however patient fail bevacizumab many treatment option . Metastases brain common intracranial tumor adult occur ten time frequently primary brain tumor . It estimate 8 - 10 % cancer patient may develop symptomatic metastatic tumor brain . Systemic therapy rarely use primary treatment brain metastasis many tumor metastasize brain chemosensitive already heavily pretreated potentially effective agent , poor penetration blood brain barrier additional concern . Dianhydrogalactitol ( DAG ) rapidly penetrate cerebrospinal fluid ( CSF ) blood-brain barrier accumulate brain tissue . Clinical study DAG patient GBM progressive secondary brain tumor warrant . Patients secondary brain metastasis allow enroll current protocol Cohorts 2 3 ; however , enrollment cease Amendment 5 continue beyond Cohort 3 . This study utilize standard 3 + 3 dose escalation design , MTD maximum specify dose reach . In Phase 2 , additional patient GBM treat MTD ( select optimum Phase 2 dose ) measure tumor responses treatment .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dianhydrogalactitol</mesh_term>
	<criteria>Patients must great equal 18 year old . Histologically confirm initial diagnosis primary WHO Grade IV malignant glioma ( glioblastoma ) , recurrent ; Cohorts 2 3 : progressive secondary brain tumor , fail standard brain radiotherapy , brain tumor progression least one line systemic therapy . Patients progressive secondary brain tumor enrol protocol follow completion Cohort 3 . If GBM , previously treat GBM surgery and/or radiation , appropriate , must fail bevacizumab ( Avastin ) temozolomide ( Temodar ) , unless either contraindicate . If GBM , great equal 12 week radiotherapy , 4 week new lesion , relative preradiation MRI , develop outside primary radiation field . Cohorts 2 &amp; 3 : Patients secondary brain tumor must great equal 4 week radiotherapy . Patients progressive secondary brain tumor enrol protocol follow completion Cohort 3 . At least 4 week last chemotherapy bevacizumab ( Avastin ) therapy ( 6 week nitrosourea mitomycin C ) , chemotherapy regime give continuously weekly basis limit potential delayed toxicity , least 2 week last dose . At least 21 day 5 halflives ( whichever short ) since prior investigational anticancer drug . A minimum 10 day termination investigational drug administration DAG require Recovered treatmentrelated toxicity Grade 1 less . Must Karnofsky performance status &gt; 50 predict life expectancy least 12 week . Must know MGMT methylation IDH1 mutation status screen study entry . Current history neoplasm entry diagnosis . Patients previous cancer treat cured local therapy alone may consider approval Medical Monitor . Evidence leptomeningeal spread disease . Evidence recent hemorrhage baseline MRI brain . Concurrent severe , intercurrent illness . History severe cardiac disease . Significant vascular disease . History stroke transient ischemic attack within 6 month prior begin treatment . Concomitant medication know inducer CYP . Concomitant medication strong inhibitor cytochrome P450 CYP3A 14 day Cycle 1 Day 1 ( pimozide , diltiazem , erythromycin , clarithromycin , quinidine , amiodarone 90 day ) Known HIV positive AIDSrelated illness . Pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>brain tumor</keyword>
	<keyword>brain cancer</keyword>
	<keyword>recurrent brain tumor</keyword>
	<keyword>recurrent brain cancer</keyword>
	<keyword>refractory brain tumor</keyword>
	<keyword>refractory brain cancer</keyword>
	<keyword>recurrent GBM</keyword>
	<keyword>refractory GBM</keyword>
	<keyword>recurrent glioma</keyword>
	<keyword>refractory glioma</keyword>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>refractory glioblastoma</keyword>
	<keyword>recurrent glioblastoma multiforme</keyword>
	<keyword>refractory glioblastoma multiforme</keyword>
	<keyword>fail temodar</keyword>
	<keyword>fail temozolomide</keyword>
	<keyword>temodar refractory</keyword>
	<keyword>temozolomide refractory</keyword>
	<keyword>fail avastin</keyword>
	<keyword>avastin refractory</keyword>
	<keyword>fail bevacizumab</keyword>
	<keyword>bevacizumab refractory</keyword>
	<keyword>avastin failure</keyword>
	<keyword>bevacizumab failure</keyword>
	<keyword>temodar failure</keyword>
	<keyword>temozolomide failure</keyword>
</DOC>